UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
MedImmune, Inc.
-------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.01 per share
- -------------------------------------------------------------------------------
(Title of Class of Securities)
584699102
-------------------------------------------------------
(CUSIP Number)
Bernd Diethelm Honer
c/o Summit Asset Management Co., Inc.
Suite 445
666 Plainsboro Rd.
Plainsboro, NJ 08536
609-275-1890
- -------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
January 9, 1997
- -------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
- -------------------------------------------------------------------------------
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box |_|
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
SCHEDULE 13D
CUSIP No. 584699102 Page 2 of 6 Pages
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Bernd Diethelm Honer
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_|
(b) |_|
3 SEC USE ONLY
4 SOURCE OF FUNDS*
PF, OO
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) |_|
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Federal Republic of Germany
NUMBER OF 7 SOLE VOTING POWER
SHARES 1,349,553
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY -0-
EACH
9 SOLE DISPOSITIVE POWER
REPORTING
1,349,553
PERSON
10 SHARED DISPOSITIVE POWER
WITH
-0-
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,349,553
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* |_|
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.2%
14 TYPE OF REPORTING PERSON*
IN
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE>
- -------------------------------------------------------------------------------
CUSIP NO. 584699102 SCHEDULE 13D Page 3 of 6 Pages
- -------------------------------------------------------------------------------
Item 1. Security and Issuer.
The title of the class of equity securities to which this Statement
relates is the Common Stock, par value $0.01 per share (the "Shares"), of
MedImmune, Inc. (the "Issuer"). The principal executive offices of the Issuer
are located at 35 West Watkins Mill Road, Gaithersburg, MD 20878.
Item 2. Identity and Background.
This Statement is being filed on behalf of Bernd Diethelm Honer. Mr.
Honer is a private investor and a citizen of the Federal Republic of Germany.
During the last five years, Mr. Honer has not been (i) convicted in a criminal
proceeding or (ii) a party to a civil proceeding of a judicial or administrative
body of competent jurisdiction and as a result of such proceeding was or is
subject to a judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, Federal or State securities laws
or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration.
On January 10, 1997, Hudson Trust, a grantor trust of which Mr. Honer
is the sole grantor ("Hudson" and, together with Mr. Honer, the "Reporting
Person"), purchased 60,000 Shares for cash consideration in the aggregate amount
of $932,500. The funds used for acquiring such Shares were from the investment
accounts of the Reporting Person. In addition, on January 9, 1997, as a result
of owning certain limited partnership interests described below, the Reporting
Person received aggregate distributions of 281,246 Shares from HealthCare
Ventures I,
<PAGE>
- -------------------------------------------------------------------------------
CUSIP NO. 584699102 SCHEDULE 13D Page 4 of 6 Pages
- -------------------------------------------------------------------------------
L.P., HealthCare Ventures II, L.P. and HealthCare Partners I, L.P.
(collectively, the "Partnerships"). Hudson is a limited partner in each of the
Partnerships.
Item 4. Purpose of Transaction.
The Reporting Person purchased the Shares, and intends to retain the
Shares received pursuant to certain partnership distributions, solely for
investment purposes. Mr. Honer expects that he will, from time to time, review
his investment position in the Issuer and may, depending on market and other
conditions, increase or decrease such investment position. He does not have any
plans or proposals with respect to any extraordinary corporate transaction
involving the Issuer or any sale of its assets or any change in its Board of
Directors, management, capitalization, dividend policy, charter or by-laws, or
any other change in its business or corporate structure or with respect to the
delisting or deregistration of any of its securities, including, without
limitation, those matters described in subparagraphs (a) through (j) of Item 4
of Schedule 13D.
Item 5. Interest in Securities of the Issuer.
(a) As of the date hereof, Mr. Honer is the beneficial owner of
1,349,553 Shares, which represents approximately 6.2% of the outstanding Shares
of the Issuer. This percentage has been calculated from information contained in
the Issuer's Quarterly Report on Form 10-Q as filed with the Securities and
Exchange Commission for the quarterly period ended September 30, 1996.
(b) Mr. Honer has sole power to vote or direct the vote and sole power
to dispose or direct the disposition of all Shares beneficially owned by him.
Mr. Honer does not share the power to vote or direct the disposition of any
Shares beneficially owned by him.
<PAGE>
- -------------------------------------------------------------------------------
CUSIP NO. 584699102 SCHEDULE 13D Page 5 of 6 Pages
- -------------------------------------------------------------------------------
(c) Other than the transactions described in this Statement, The
Reporting Person has not effected any other transactions in the Shares during
the 60 days preceding January 10, 1997 or subsequently thereto.
(d) None.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or
Relationships with Respect to Securities of the Issuer.
None.
Item 7. Material to be filed as Exhibits.
None.
<PAGE>
- -------------------------------------------------------------------------------
CUSIP NO. 584699102 SCHEDULE 13D Page 6 of 6 Pages
- -------------------------------------------------------------------------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
hereby certify that the information set forth in this Statement is true,
complete and correct.
Dated: January 21, 1997 BERND DIETHELM HONER
By: /s/ Peter M. Rup
Peter M. Rup, as duly
authorized attorney-in-fact*
- --------
* Power of attorney has been previously filed with the Securities and
Exchange Commission in connection with the Reporting Person's Schedule 13G
and is incorporated by reference herein.
